AIM ImmunoTech Inc

AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AIM ImmunoTech reports promising clinical progress and financial stability

AIM ImmunoTech demonstrated strong clinical progress and financial stability, positioning the company well for future growth and potential partnerships.
While facing regulatory and operational challenges, the company's focus on expanding Ampligen's therapeutic applications and medical expertise presents significant opportunities for advancement.
Investors should monitor AIM ImmunoTech's continued progress in clinical trials and regulatory interactions, as positive outcomes could drive value creation and market expansion.

AIM ImmunoTech reports positive clinical progress and solid financial standing

AIM ImmunoTech's Q2 2024 Earnings Call highlighted significant progress in clinical trials for Ampligen, particularly in oncology indications.
Financially, the company maintains a solid cash position and continues to manage expenses to support ongoing operations and future milestones.
While facing challenges in trial design and cost management, AIM ImmunoTech remains well-positioned to capitalize on opportunities for growth and partnership.

AIM ImmunoTech advances Ampligen with positive clinical data amid challenges

AIM ImmunoTech's Q3 showcased progress in Ampligen's development, with promising data supporting its therapeutic potential. While facing financial challenges, the company is focused on leveraging opportunities for collaborations and commercialization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avid Bioservices

CytoDyn Inc.

Fulgent Genetics

Humanigen

Jaguar Health

PureTech Health PLC

Keep in mind downside risk, if their respective candidates fail to pan out. But, there may be opportunity with these seven biotech stocks targeting treatments for long-haul Covid-19.

7 Biotech Stocks Focused on Chronic Covid Treatment

AIM ImmunoTech Inc. (NYSEAMERICAN:AIM) said it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of its drug Ampligen as an intranasal therapy. The company said this is a critical step in its ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for coronavirus (COVID-19) and other respiratory viral diseases.

AIM ImmunoTech receives required Ethics Committee approval in the Netherlands to commence its Phase 1 clinical study for Ampligen as an intranasal therapy

OCALA, Fla., Feb. 16, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has received approval from the required Ethics Committee in the Netherlands to commence its Phase 1 clinical study on the safety of AIM's drug Ampligen as an intranasal therapy, a critical step in the company's ongoing efforts to develop Ampligen as a potential prophylaxis or treatment for COVID-19 and other respiratory viral diseases.

AIM ImmunoTech Announces Ethics Committee Approval to Commence Phase 1 Clinical Study of Ampligen as an Intranasal Therapy

AIM ImmunoTech Inc (NYSE: AIM) shares are rising today after the company announced that the Netherlands regulatory authority had approved treatment for six pancreatic cancer patients as part of a new, follow-up Early Access Program (EAP). Subject to further authorization, the company plans to treat up to 16 pancreatic cancer patients with rintatolimod (Ampligen) under the EAP.

AIM ImmunoTech To Include New Patients In Netherlands Pancreatic Cancer Program

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) announced Wednesday that the Dutch Health and Youth Care Inspectorate (IGJ) has approved use of its treatment for six pancreatic cancer patients as part of a new, follow-up Early Access Program (EAP) at Erasmus Medical Center in the Netherlands.  Subject to further authorization, AIM ImmunoTech said it plans to treat up to 16 pancreatic cancer patients with rintatolimod (Ampligen) under the EAP, which follows the success of a previous multi-year Ampligen EAP for pancreatic cancer patients at Erasmus.

AIM ImmunoTech announces expansion of its pancreatic cancer program to include new patients in the Netherlands

Early Access Program Will Also Allow Further Treatment of Patients Treated Under the Previous Ampligen Early Access Program Early Access Program Will Also Allow Further Treatment of Patients Treated Under the Previous Ampligen Early Access Program

AIM ImmunoTech Announces the Expansion of its Pancreatic Cancer Program to Include New Patients in the Netherlands

AIM ImmunoTech Inc (NYSEAMERICAN:AIM) (FRA:HXB2) said it has completed its At-The-Market (ATM) facility and close the ATM's Equity Distribution Agreement (EDA).  The company, which focuses on developing therapies to treat multiple types of cancers, immune disorders, and viral diseases, including coronavirus (COVID-19), said it believes, based on its current financial condition, that it has adequate funds to meet its anticipated operational cash needs and fund its current clinical trials over approximately the next 24 months.

AIM ImmunoTech completes and closes ATM facility, says current capital expected to meet needs for clinical trials

OCALA, Fla., Feb. 05, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that it has completed its At-The-Market (ATM) facility and closed the ATM's Equity Distribution Agreement (EDA). Management believes, based on the company's current financial condition, that it has adequate funds to meet its anticipated operational cash needs and fund current clinical trials over approximately the next twenty-four months.

AIM ImmunoTech Completes and Closes ATM Facility; Current Capital Expected to Meet Needs for Current Clinical Trials

AIM is Working to Develop an Effective COVID-19 Intranasal Therapy AIM is Working to Develop an Effective COVID-19 Intranasal Therapy

AIM ImmunoTech Enters into Agreement for Proposed Intranasal Safety Study of Ampligen

AIM to discuss AMP-511 trial which includes COVID-19-induced chronic fatigue “long hauler” patients and other upcoming milestones AIM to discuss AMP-511 trial which includes COVID-19-induced chronic fatigue “long hauler” patients and other upcoming milestones

AIM ImmunoTech Reschedules Investor Conference Call to January 21, 2021 at 11AM ET

OCALA, Fla., Jan. 11, 2021 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) and its CEO Thomas K. Equels today announced that this week's planned investor conference call will be postponed and rescheduled for a later date following the death of Mr. Equels' mother over this past weekend.

AIM ImmunoTech Postpones Investor Conference Call. Will Reschedule for a Later Date

AIM to host investor conference call on January 12, 2021 at 11AM ET to discuss developments with AMP-511 trial and provide update on other major achievements and upcoming milestones AIM to host investor conference call on January 12, 2021 at 11AM ET to discuss developments with AMP-511 trial and provide update on other major achievements and upcoming milestones

AIM ImmunoTech Announces First COVID-19-Induced Chronic Fatigue “Long Hauler” Patient Dosed with Ampligen

Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects

AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers'

AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 ‘Long Haulers' Institutional Review Board Authorizes Public Notification for Potential Enrollment of Subjects OCALA, FL / ACCESSWIRE / December 24, 2020 / AIM ImmunoTech Inc. (NYSE American:AIM) announced today that the post-COVID-19 "Long Hauler" portion of the active AMP-511 Expanded Access Program (EAP) protocol received approval from the Institutional Review Board (IRB) for a public notification of potential patient enrollment. Eligible patients enrolled in the trial receive treatment with AIM's flagship pipeline drug Ampligen.

AIM ImmunoTech Announces Availability of the ME/CFS Clinical Trial of its Drug Ampligen for Enrollment to COVID-19 Long Haulers

OCALA, Fla., Dec. 21, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today announced that the U.S. Food and Drug Administration on December 17, 2020 granted Orphan Drug Designation status to AIM's drug Ampligen (rintatolimod) for the treatment of pancreatic cancer.

AIM ImmunoTech Inc.'s Drug Ampligen Awarded FDA's Orphan Drug Designation Status for the Treatment of Pancreatic Cancer

AnPac Bio-Medical Science Co

Renalytix AI plc

AIM ImmunoTech (NYSE: AIM) shares are trading higher on Wednesday after the company dosed its first patient in a study evaluating ampligen as part of combination treatment for patients with cancer and COVID-19. AIM ImmunoTech is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases.

Why These 3 Health Care Stocks Are Trading Higher Today

OCALA, Fla., Nov. 25, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced developments in its work to develop new treatments or preventive strategies for COVID-19, the disease caused by SARS-CoV-2.

AIM Announces Milestone in COVID-19 Treatment and Prevention Efforts with First Patient Dosed in Study Evaluating Ampligen as Part of Combination Treatment for Patients with Cancer and COVID-19

OCALA, Fla., Nov. 13, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM), an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers, today provided a business update for the third quarter ended September 30, 2020.

AIM ImmunoTech Provides Third Quarter 2020 Business Update

Early Onset Therapy May Be Key to COVID Long Hauler Syndrome Early Onset Therapy May Be Key to COVID Long Hauler Syndrome

AIM ImmunoTech Announces PLOS ONE's Publication of New Data Analyses Showing Importance of Disease Duration on Ampligen's Positive Role in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

TAMPA, Fla. and OCALA, Fla., Oct. 30, 2020 (GLOBE NEWSWIRE) -- BioFlorida has announced Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech Inc. (NYSE American: AIM), as its Weaver H. Gaines Entrepreneur of the Year. The Entrepreneur of the Year Award recognizes an entrepreneur who has made extraordinary contributions to the growth of life sciences in the leadership of a company or institution. BioFlorida represents 6,700 establishments and research organizations in the biopharmaceuticals, medical technology, healthIT and bioagriculture sectors.

BioFlorida Names AIM ImmunoTech CEO Thomas K. Equels as Entrepreneur of the Year

OCALA, Fla. , Oct. 22, 2020 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) today announced that Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech, is scheduled to participate in a virtual panel titled, “COVID-19: Progress on Treatments & Prevention” on Thursday, October 29, at 10:05 A.M. Eastern Time at the 23rd Annual BioFlorida Conference. The presentation will be webcast live on the conference event platform, which can be accessed here.

AIM ImmunoTech CEO to Participate in Virtual Panel Presentation at the 23rd Annual BioFlorida Conference on October 29th

COVID-19 Patients May Continue to Experience Chronic Fatigue-Like Symptoms COVID-19 Patients May Continue to Experience Chronic Fatigue-Like Symptoms

AIM ImmunoTech Announces IRB Approval to Enroll COVID-19 ‘Long Haulers’ in the AMP-511 ME/CFS Clinical Trial of Ampligen

Aim ImmunoTech (AIM) is in the news Tuesday after positive results from an Early Access Program (EAP) sent AIM stock soaring higher.
The post Aim ImmunoTech News: Why AIM Stock Is Shooting 22% Higher Today appeared first on InvestorPlace.

Aim ImmunoTech News: Why AIM Stock Is Shooting 22% Higher Today

One of the things that's been keeping interest in AIM somewhat strong since that March plunge is that no company has pinned down an effective coronavirus treatment or vaccine. It's not a stretch to say some ambitious, risk-tolerant investors may be looking at AIM through the lens of the “door's open, why not AIM?

AIM ImmunoTech Seduces With Coronavirus Treatment Potential

Altimmune

Brighthouse Financial

SG Blocks

Soleno Therapeutics

As the Nasdaq continues its historic climb,  the Dow has erased some of Monday's gains. The coronavirus will continue to make headlines as its cases grow at a consistent rate across 23 states.

News for AIM ImmunoTech Inc Stock (AIM)